Business Context and Reporting Period
Company: Whitehorse Finance, Inc. (a Business Development Company and Regulated Investment Company)
Reporting Period: Quarterly period ended June 30, 2013 (Form 10-Q)
Business Model: Externally managed closed-end fund investing primarily in senior secured loans (first and second lien) to performing small-cap companies in North America. The company utilizes leverage through a credit facility and term loans to enhance returns.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2013 | Three Months Ended June 30, 2013 | As of June 30, 2013 |
|---|---|---|---|
| Total Investment Income | $17.88 million | $9.50 million | - |
| Total Expenses | $9.02 million | $4.65 million | - |
| Net Investment Income | $8.86 million | $4.85 million | - |
| Net Increase in Net Assets (Operations) | $6.68 million | $3.17 million | - |
| Net Asset Value (NAV) per Share | - | - | $15.04 |
| Total Assets | - | - | $348.41 million |
| Total Liabilities | - | - | $123.31 million |
| Total Net Assets | - | - | $225.10 million |
| Cash and Cash Equivalents | - | - | $91.34 million (Unrestricted: $91.34m; Restricted: $11.99m) |
| Debt Outstanding | - | - | $111.25 million ($21.25m Credit Facility; $90.00m Term Loan) |
| Portfolio Fair Value | - | - | $237.74 million |
Material Changes vs. Prior Period
- Portfolio Growth: Investment portfolio fair value increased from $180.49 million (Dec 31, 2012) to $237.74 million (June 30, 2013), driven by new originations of $43.35 million and purchases of $30.13 million.
- Expense Structure: Expenses rose significantly compared to the prior year due to the implementation of the Investment Advisory Agreement and debt financing post-IPO. Total expenses for the six months ended June 30, 2013, were $9.02 million versus $0.48 million in the same period in 2012 (when the company was pre-IPO and fees were waived).
- Unrealized Losses: The company recorded a net unrealized depreciation of $2.18 million for the six months ended June 30, 2013, contrasting with a net unrealized appreciation of $2.09 million in the same period in 2012. This was attributed to accretion of discounts and negative credit-related adjustments.
- Liquidity: Cash and cash equivalents decreased from $156.12 million to $91.34 million, primarily due to investment acquisitions and debt repayments.
Guidance, Outlook, and Risks
- Subsequent Events (Debt Refinancing): In July 2013, the company completed a public offering of $30.0 million of 6.50% Senior Notes due 2020. Proceeds were used to reduce the unsecured term loan. The term loan was also amended to lower the interest rate to LIBOR + 2.20% and extend the maturity to July 3, 2015.
- Dividends: Distributions declared were $0.71 per share for the six months ended June 30, 2013. A portion of these distributions ($0.04 per share) was estimated to be a return of capital for tax purposes.
- Portfolio Composition: As of June 30, 2013, 80.1% of the portfolio consisted of variable-rate investments indexed to LIBOR, positioning the company for a rising rate environment. The weighted average cash yield was 14.0%.
- Risk Factors: Key risks include credit risk (borrower default), market risk (interest rate fluctuations), and the reliance on the investment adviser (H.I.G. WhiteHorse Advisers, LLC). The company notes that valuations of privately held investments are inherently uncertain and based on significant management judgment (Level 3 inputs).
Investor Verification Checklist
- Debt Covenants: Verify the company's continued compliance with asset coverage ratios (currently 302.3%) and leverage restrictions under the Credit Facility and Term Loan.
- Valuation Methodology: Review the specific assumptions used for Level 3 fair value measurements, particularly the discount rates (weighted average 16.1% for first lien loans) and the impact of credit adjustments on unrealized losses.
- Return of Capital: Monitor future tax reporting (Form 1099-DIV) to confirm the actual tax characterization of distributions, as a portion may be a return of capital rather than ordinary income.
- Concentration Risk: Assess the impact of the top holdings, specifically Acella Pharmaceuticals (26.51% of net assets) and GMT Holdings (13.18% of net assets), on overall portfolio performance.
- Interest Rate Sensitivity: Evaluate the impact of rising LIBOR rates on net investment income, noting that most loans have floors which may delay the benefit of rate increases.